Finance

Lists
OXB:LON
Oxford BioMedica plc
GBX 449,50
-2,49%
(-11,50) 1D
16 Sep., 16:35:18 GMT+1  ·   GBX
All symbols
SymbolPriceChange% Change
Generating top insights for OXB...
Open
GBX 455,50
High
GBX 462,50
Low
GBX 437,25
Mkt. cap
544,12 m
Avg. vol.
1,00 m
Volume
804,29 k
52-wk high
GBX 962,00
52-wk low
GBX 420,00
EPS
-GBX 0,27
Shares outstanding
121,05 m
No. of employees
977
Open
GBX 455,50
High
GBX 462,50
Low
GBX 437,25
Mkt. cap
544,12 m
Avg. vol.
1,00 m
Volume
804,29 k
52-wk high
GBX 962,00
52-wk low
GBX 420,00
EPS
-GBX 0,27
Shares outstanding
121,05 m
No. of employees
977
Profile
Oxford Biomedica is a gene and cell therapy company specialising in the development of gene-based medicines. It is listed on the London Stock Exchange and is a constituent of the FTSE 250 Index. Wikipedia
About Oxford BioMedica plc
CEOFrank Mathias
Employees977
Founded1995
Headquarters-
Sector-
Websiteoxb.com
Previous reportsAll values in GBP
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in GBP
Mrt. 2025
Jun. 2025
Sep. 2025
Des. 2025
Revenue
36,61 m
36,61 m
47,76 m
47,76 m
Cost of goods sold
20,78 m
20,78 m
30,60 m
30,60 m
Cost of revenue
20,78 m
20,78 m
30,60 m
30,60 m
Research and development expenses
992,00 k
992,00 k
1,54 m
1,54 m
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
26,93 m
26,93 m
19,65 m
19,65 m
Operating expense
27,62 m
27,62 m
20,93 m
20,93 m
Total operating expenses
48,40 m
48,40 m
51,52 m
51,52 m
Operating income
-11,79 m
-11,79 m
-3,76 m
-3,76 m
Other non operating income
-63,50 k
-63,50 k
-323,00 k
-323,00 k
EBT including unusual items
-13,02 m
-13,02 m
-2,95 m
-2,95 m
EBT excluding unusual items
-13,02 m
-13,02 m
-7,26 m
-7,26 m
Income tax expense
423,50 k
423,50 k
-1,07 m
-1,07 m
Effective tax rate
-3,25%
-3,25%
36,20%
36,20%
Other operating expenses
-311,50 k
-311,50 k
-259,50 k
-259,50 k
Net income
-13,18 m
-13,18 m
-1,88 m
-1,88 m
Net profit margin
-36,00%
-36,00%
-3,94%
-3,94%
Earnings per share
-
-
-
-
Interest and investment income
538,00 k
538,00 k
649,50 k
649,50 k
Interest expense
-3,38 m
-3,38 m
-3,55 m
-3,55 m
Net interest expenses
-2,84 m
-2,84 m
-2,90 m
-2,90 m
Depreciation and amortization charges
-
-
-
-
EBITDA
-7,07 m
-7,07 m
-2,06 m
-2,06 m
Gain or loss from assets sale
-43,00 k
-43,00 k
53,00 k
53,00 k
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google-programme